M Silverman1, M Wang, G Hunter, N Taub. 1. Department of Child Health, Institute for Lung Health, Leicester University, Leicester, UK. ms70@le.ac.uk
Abstract
BACKGROUND: The effect of prophylactic nasal corticosteroids on wheezing episodes associated with colds was investigated in a 12 week parallel group, double blind, randomised controlled trial in preschool children. METHODS: Data were collected from 50 children aged 12-54 months with a history of at least three episodes of wheeze associated with colds over the previous winter, but few or no interval symptoms; 24 were given one dose offluticasone aqueous nasal spray (50 micro g) into each nostril twice daily and 26 received an indistinguishable placebo spray. Episodes of lower respiratory illness occurring within 2 days of the onset of a cold were identified from daily symptom diaries. The main outcome was nocturnal symptom score during the first 7 days of an episode. RESULTS: The groups were well balanced on entry except that the treatment group had a history of more prolonged episodes. During the trial there was no significant difference in the number of episodes in the treatment and control groups (27 and 37, respectively), in the severity of nocturnal symptoms (mean score 1.33 and 1.22, respectively, confidence interval of difference -0.24 to +0.47) or in daytime symptoms, activity or total scores during episodes. Compliance was estimated to be over 50% in 43 of the children. CONCLUSIONS:Nasal corticosteroid treatment does not prevent acute wheezy episodes associated with upper respiratory infections (common colds) in preschool children.
RCT Entities:
BACKGROUND: The effect of prophylactic nasal corticosteroids on wheezing episodes associated with colds was investigated in a 12 week parallel group, double blind, randomised controlled trial in preschool children. METHODS: Data were collected from 50 children aged 12-54 months with a history of at least three episodes of wheeze associated with colds over the previous winter, but few or no interval symptoms; 24 were given one dose of fluticasone aqueous nasal spray (50 micro g) into each nostril twice daily and 26 received an indistinguishable placebo spray. Episodes of lower respiratory illness occurring within 2 days of the onset of a cold were identified from daily symptom diaries. The main outcome was nocturnal symptom score during the first 7 days of an episode. RESULTS: The groups were well balanced on entry except that the treatment group had a history of more prolonged episodes. During the trial there was no significant difference in the number of episodes in the treatment and control groups (27 and 37, respectively), in the severity of nocturnal symptoms (mean score 1.33 and 1.22, respectively, confidence interval of difference -0.24 to +0.47) or in daytime symptoms, activity or total scores during episodes. Compliance was estimated to be over 50% in 43 of the children. CONCLUSIONS: Nasal corticosteroid treatment does not prevent acute wheezy episodes associated with upper respiratory infections (common colds) in preschool children.
Authors: N G Papadopoulos; P J Bates; P G Bardin; A Papi; S H Leir; D J Fraenkel; J Meyer; P M Lackie; G Sanderson; S T Holgate; S L Johnston Journal: J Infect Dis Date: 2000-06-05 Impact factor: 5.226
Authors: J Grossman; C Banov; E A Bronsky; R A Nathan; D Pearlman; J A Winder; P H Ratner; L Mendelson; S R Findlay; K M Kral Journal: Pediatrics Date: 1993-10 Impact factor: 7.124
Authors: Jakob Usemann; Binbin Xu; Edgar Delgado-Eckert; Insa Korten; Pinelopi Anagnostopoulou; Olga Gorlanova; Claudia Kuehni; Martin Röösli; Philipp Latzin; Urs Frey Journal: ERJ Open Res Date: 2018-11-20
Authors: N A Geppe; B M Blokhin; O V Shamsheva; S T Abdrakhmanova; K A Alikhanova; G T Myrzabekova Journal: Can Respir J Date: 2021-11-15 Impact factor: 2.409
Authors: Jakob Usemann; Urs Frey; Ines Mack; Anne Schmidt; Olga Gorlanova; Martin Röösli; Dominik Hartl; Philipp Latzin Journal: BMC Pulm Med Date: 2016-05-18 Impact factor: 3.317
Authors: Luregn Jan Schlapbach; Philipp Latzin; Nicolas Regamey; Claudia E Kuehni; Marcel Zwahlen; Carmen Casaulta; Christoph Aebi; Urs Frey Journal: Pediatr Allergy Immunol Date: 2008-08-12 Impact factor: 6.377